ME/CFS and the Gut Microbiome: The Latest Research

ME/CFS and the Gut Microbiome: What the Latest Research Reveals About Butyrate, Fatigue, and Your Gut Bacteria

If you live with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), you know that conventional medicine often falls short of meaningful answers. The exhaustion is real, the brain fog is real, and the gastrointestinal symptoms so many people experience are real — yet so much of it remains poorly understood by mainstream healthcare.

That’s precisely why a landmark study published in Cell Host & Microbe in 2023 matters. This research represents one of the most rigorous investigations into the gut microbiome in ME/CFS to date — and what it found has significant implications for how we understand, and potentially support, this debilitating condition.

In this post, I’m going to break down the key findings from this study in plain language, explain why they matter clinically, and share what you can do right now to start investigating your own gut health.

📌 Key Takeaway: People with ME/CFS show a consistent pattern of gut dysbiosis — particularly a deficiency in butyrate-producing bacteria — and this deficiency is directly linked to the severity of fatigue symptoms.

About the Study: The Largest ME/CFS Gut Microbiome Analysis to Date

The research, led by Guo et al. at Columbia University’s Mailman School of Public Health, analysed stool samples from 106 people with ME/CFS and 91 healthy matched controls — making it the largest prospective case-control study of its kind. [1]

What made this study particularly robust was its methodology. Rather than relying on basic 16S rRNA gene sequencing (which only identifies bacteria at the genus level), the researchers used:

• Shotgun metagenomics — providing species-level identification and functional pathway analysis
• qPCR (quantitative PCR) — measuring actual quantities of specific bacterial species in the gut
• Metabolomics — directly measuring short-chain fatty acid (SCFA) concentrations in stool
• Machine learning classifiers — to validate whether microbiome patterns could reliably distinguish ME/CFS from healthy controls

All participants met both the 1994 CDC and 2003 Canadian Consensus criteria for ME/CFS. Controls were matched for age, sex, geography, and socioeconomic status. Antibiotic use within six weeks of testing was an exclusion criterion. This is as methodologically sound as microbiome research gets.

What Is ME/CFS? A Brief Clinical Overview

ME/CFS is a complex, chronic, multisystem disease characterised by:

• Persistent, debilitating fatigue not relieved by rest
• Post-exertional malaise (worsening of symptoms after physical or cognitive exertion)
• Cognitive dysfunction and brain fog
• Sleep disturbances
• Gastrointestinal symptoms
• Orthostatic intolerance

The global prevalence ranges from 0.4% to 2.5%, with an estimated 2.5 million sufferers in the US alone. The condition disproportionately affects women at a ratio of approximately 3:1. Onset is most common in adults aged 20–40, and symptoms are frequently preceded by a viral-like illness — a pattern that has gained renewed interest in the context of Long COVID. [1]

Despite its profound impact on quality of life, ME/CFS lacks a definitive biomarker, a clear aetiology, and effective treatments. This is exactly what makes gut microbiome research in this population so exciting — it offers a measurable, functional window into the biology of the condition.

Key Findings: What the Research Revealed

1. Profound Gut Dysbiosis in ME/CFS

ME/CFS patients showed significant differences in gut microbiome composition compared to healthy controls. While overall species richness was similar, beta diversity — the compositional structure of the microbiome — was meaningfully different, even after controlling for potential confounders like IBS, age, sex, BMI, and antibiotic use.

Alpha diversity (Shannon index and evenness) was lower in ME/CFS patients who also had self-reported IBS, highlighting the importance of distinguishing ME/CFS with and without comorbid IBS when interpreting microbiome data.

🔬 Clinical note: This finding reinforces something I see regularly in clinical practice — ME/CFS and IBS frequently co-occur, and the gut microbiome profile in these individuals is often more disturbed than in those with ME/CFS alone. This is why comprehensive microbiome testing, not basic stool analysis, is so important.

2. Dramatic Reductions in Key Butyrate-Producing Bacteria

This is the headline finding of the paper. Two species were consistently and significantly lower in ME/CFS patients compared to healthy controls:

• Faecalibacterium prausnitzii — arguably the most important butyrate-producing bacterium in the human gut
• Eubacterium rectale — another major short-chain fatty acid producer

These reductions were confirmed by two independent methods: relative abundance from metagenomics, and absolute quantification via qPCR. The qPCR data is particularly important — it means we’re not just seeing a proportional shift due to overgrowth of other species, but a genuine reduction in the actual number of these bacteria in the gut.

Both F. prausnitzii and E. rectale belong to the butyrate-producing community of the gut — a functionally critical group of microorganisms that use dietary fibre (particularly resistant starch and inulin-type fructans) to produce butyrate via the acetyl-CoA pathway.

3. Deficient Butyrate Production at the Metabolic Level

The researchers didn’t stop at identifying which bacteria were missing. They went further by analysing the functional capacity of the microbiome — essentially asking: does the ME/CFS microbiome have the genetic machinery to produce butyrate?

The answer was a clear no. Functional metagenomic analysis showed that genes along the acetyl-CoA pathway — the primary route for bacterial butyrate synthesis — were significantly depleted across nearly every step of the pathway in ME/CFS patients.

This was then confirmed metabolically: stool concentrations of butyrate were significantly lower in ME/CFS patients, independent of IBS status. Acetate was also lower, particularly in those with comorbid IBS.

The acetyl-CoA pathway is quantitatively the dominant route for butyrate production in the human colon, primarily driven by Eubacterium, Roseburia, and Faecalibacterium species. When these bacteria decline, the downstream consequences for gut health are substantial.

Are low butyrate-producing bacteria affecting your energy and gut health? Find Out Here.

Shop our gut health tests

4. F. prausnitzii Abundance Directly Correlates with Fatigue Severity

Perhaps the most clinically striking finding: the abundance of Faecalibacterium prausnitzii was inversely associated with fatigue severity across multiple dimensions of the Multidimensional Fatigue Inventory (MFI). The lower the F. prausnitzii, the worse the fatigue — including general fatigue, physical fatigue, and reduced activity scores.

This species-symptom association remained significant after adjusting for covariates including IBS, medication use, age, sex, and geography. This is not a correlational artefact — it held up under rigorous statistical scrutiny.

This is consistent with evidence from other conditions. Studies in IBD, for example, have shown that fatigued IBD patients have lower F. prausnitzii than non-fatigued IBD patients, and large population studies have associated higher Faecalibacterium abundance with better quality of life and reduced rates of depression. [4, 5]

5. Disrupted Microbiome Network Architecture

Beyond species abundances, the researchers mapped the ecological relationships between bacterial species — creating co-abundance networks that reveal how bacteria interact with one another.

In healthy controls, the microbiome showed a well-organised community structure. In ME/CFS, this structure was extensively disrupted:

• 42 species shifted between network modules
• F. prausnitzii became a more central hub in the ME/CFS network — but surrounded by more negative (competitive or antagonistic) interactions
• Ruminococcus gnavus (elevated in ME/CFS) formed a new direct negative edge with F. prausnitzii, potentially suppressing it
• Clostridium bolteae (also elevated in ME/CFS) was similarly associated with negative interactions around F. prausnitzii

This network rewiring tells us that ME/CFS dysbiosis isn’t simply about individual species going up or down — it’s a fundamental reorganisation of the microbial ecosystem.

6. Machine Learning Can Identify ME/CFS from Microbiome Profiles

Using twelve differentially abundant species, the research team trained machine learning classifiers that achieved AUC scores of approximately 0.80 — meaning the model could correctly distinguish ME/CFS from healthy controls 80% of the time based on microbiome data alone.

Importantly, these models were geographically robust (tested across five US sites) and validated in an independent external cohort from years earlier. This level of reproducibility is unusual in microbiome research and significantly strengthens the clinical relevance of the findings.

Why Butyrate Matters So Much: A Functional Medicine Perspective

Butyrate is far more than a microbial waste product. It is arguably the most important SCFA produced in the human colon, with wide-ranging effects on gut, immune, and systemic health.

Colonocyte Energy

Butyrate is the primary fuel source for colonocytes — the cells lining your colon — providing approximately 70% of their energy needs. When butyrate is deficient, colonocyte function deteriorates, which can compromise every aspect of gut barrier integrity.

Gut Barrier Function

Butyrate directly regulates tight junction proteins and Hypoxia-Inducible Factor (HIF)-1, both of which are critical for maintaining an intact intestinal barrier. Low butyrate = increased intestinal permeability. Prior research in ME/CFS has already shown elevated plasma lipopolysaccharides (LPS) — a marker of microbial translocation — suggesting that gut barrier disruption is a feature of the condition. [1] This study provides a plausible mechanism for that finding: deficient butyrate.

Immune Modulation

Butyrate promotes regulatory T cell (Treg) differentiation, inhibits pro-inflammatory cytokine production, and activates antimicrobial activity in intestinal macrophages. Given the documented immune dysregulation in ME/CFS — including autoantibodies and altered immune responses — this pathway is highly relevant.

Epigenetics and Cell Proliferation

As a histone deacetylase (HDAC) inhibitor, butyrate influences gene expression across multiple systems. It suppresses cancer cell proliferation, supports stem cell renewal in the gut lining, and has broad epigenetic effects that extend well beyond the intestine.

Antimicrobial Control

Butyrate stimulates the production of endogenous antimicrobial peptides and enhances macrophage antimicrobial activity. Interestingly, ME/CFS patients in this study had a higher total bacterial load in stool — a finding the researchers attribute plausibly to loss of butyrate-mediated bacterial growth control.

💡 Clinical insight: In my practice, I frequently see clients with ME/CFS or profound fatigue who present with markers of gut barrier dysfunction, immune activation, and disrupted SCFA production on microbiome testing. This research gives us a much clearer mechanistic picture of why these patterns matter — and where to focus therapeutically.

The Bacteria That Were Elevated in ME/CFS — And Why They Matter

While the reductions in butyrate producers are the headline, several species were found in greater abundance in ME/CFS patients. Understanding these is equally important.

Ruminococcus gnavus

A mucin-degrading bacterium that produces an inflammatory polysaccharide and secondary bile acids. R. gnavus has been associated with inflammatory bowel disease and now, via this study, with ME/CFS. Its negative network interaction with F. prausnitzii suggests it may actively compete with or suppress beneficial butyrate producers.

Clostridium bolteae

Previously associated with autism spectrum disorder, multiple sclerosis, and atopic conditions. In MS, C. bolteae abundance correlates positively with fatigue — a pattern that mirrors what we see in ME/CFS.

Ruthenibacterium lactatiformans

A lactate producer. The functional metagenomic data in this study showed increased lactate production capacity in ME/CFS — which, in the context of depleted butyrate producers, may reflect a shift in the metabolic ecology of the gut away from SCFA production and towards alternative fermentation pathways.

What Does This Mean in Practice?

This research moves us meaningfully forward in understanding ME/CFS — but it also raises important clinical questions. Here is how I interpret these findings in the context of supporting clients with ME/CFS and chronic fatigue.

1. Gut Health Is Not Peripheral in ME/CFS — It Is Central

The gut microbiome is not a side issue or a secondary consideration in ME/CFS. The scale and functional nature of the dysbiosis documented here — with direct links to fatigue severity — places gut health at the centre of the picture. Investigating and addressing gut dysbiosis should be part of any comprehensive ME/CFS workup.

2. Generic Probiotic Recommendations Are Not Enough

While probiotics have a role, F. prausnitzii cannot currently be delivered directly as a probiotic supplement — it is an obligate anaerobe that does not survive standard manufacturing processes. Supporting its growth requires a different approach: targeted dietary strategies and, in some cases, specific prebiotics that preferentially feed F. prausnitzii and the broader butyrate-producing community.

Recommended Product: PHGG

3. Testing Matters

You cannot optimise what you cannot measure. Knowing your personal microbiome profile — including the abundance of F. prausnitzii, Roseburia, Eubacterium, and other butyrate producers — allows for genuinely targeted intervention rather than guesswork.

Want to know more about your gut health? Find Out Here.

Shop our gut health tests

4. Dietary and Lifestyle Foundations

The research team notes that reduced physical activity — a consequence of ME/CFS symptoms — may itself contribute to microbiome changes, including reductions in butyrate producers. This creates a challenging feedback loop, but it also highlights the importance of addressing all modifiable factors, however small.

From a dietary perspective, the evidence consistently points to the importance of:

• Fermentable fibre from diverse plant foods (resistant starch, inulin, pectin)
• Polyphenol-rich foods (berries, green tea, olive oil)
• Reduced ultra-processed food intake
• Adequate dietary variety to support microbial diversity
• Omega 3 fatty acids support butyrate producing bacteria

Study Limitations: What We Don’t Yet Know

Good science acknowledges its limits, and I want to be transparent about what this study cannot tell us:

• Causation vs. consequence: Does low F. prausnitzii cause worse fatigue, or does the severity of ME/CFS (and resulting reduced activity) cause the microbiome to deteriorate? The researchers themselves raise this question, and it likely operates in both directions — a vicious cycle.
• Cross-sectional design: This is a snapshot in time. We cannot determine when in the illness course these changes occur, or whether they are stable over time.
• US-based cohort: While geographically diverse within the US, we need validation in European and global populations.
• Dietary data: Diet was not fully controlled for, and dietary factors are among the strongest determinants of microbiome composition.
• Treatment implications: The study identifies targets, but does not yet tell us whether intervening on the microbiome will improve ME/CFS outcomes. That research is needed urgently.

Conclusion: A Meaningful Step Forward

The Guo et al. study represents a significant and genuinely exciting development in ME/CFS research. For the first time, we have large-scale, multi-omic evidence that gut dysbiosis in ME/CFS is not incidental — it is functional, measurable, and directly linked to the cardinal symptom of the condition: fatigue.

The depletion of Faecalibacterium prausnitzii and Eubacterium rectale, the resulting deficiency in butyrate synthesis, the disruption of gut barrier function, and the reorganisation of microbial network ecology all point to the gut as a meaningful driver — or at least a significant amplifier — of ME/CFS pathophysiology.

This does not mean the gut microbiome is the entire story of ME/CFS. The illness is multisystem, and the dysbiosis we see may be both cause and consequence. But it does mean that the gut is a genuinely actionable target — one we can measure, monitor, and in many cases, meaningfully support.

A Functional Medicine approach has always been to investigate the root drivers of symptoms rather than simply managing them. This research reinforces that commitment. If you are struggling with ME/CFS, chronic fatigue, or unexplained gut symptoms, understanding your gut microbiome is not an optional extra — it is foundational.

References

[1] Guo C, Che X, Briese T, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe. 2023;31(2):288-304.e8. doi:10.1016/j.chom.2023.01.004

[2] Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. 2021;27(9):895-906.

[3] Vital M, Karch A, Pieper DH. Colonic butyrate-producing communities in humans: an overview using omics data. mSystems. 2017;2(6):e00130-17.

[4] Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632.

[5] Borren NZ, Plichta D, Joshi AD, et al. Alterations in fecal microbiomes and serum metabolomes of fatigued patients with quiescent inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(3):519-527.e5.

[6] Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.

[7] Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841-852.

[8] Miquel S, Martin R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255-261.